이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!
Jubilant Pharmova 대차 대조표 상태
재무 상태 기준 확인 3/6
Jubilant Pharmova 의 총 주주 지분은 ₹54.2B 이고 총 부채는 ₹34.1B, 이는 부채 대 자기자본 비율을 63% 로 가져옵니다. 총자산과 총부채는 각각 ₹115.5B 및 ₹61.3B 입니다. Jubilant Pharmova 의 EBIT는 ₹5.2B 이며 이자보상배율은 1.9 입니다. ₹9.6B 의 현금 및 단기 투자금을 보유하고 있습니다.
주요 정보
63.0%
부채 비율
₹34.14b
부채
| 이자 보상 비율 | 1.9x |
| 현금 | ₹9.57b |
| 주식 | ₹54.21b |
| 총 부채 | ₹61.27b |
| 총 자산 | ₹115.49b |
최근 재무 상태 업데이트
Jubilant Pharmova (NSE:JUBLPHARMA) Has A Somewhat Strained Balance Sheet
Mar 14
These 4 Measures Indicate That Jubilant Pharmova (NSE:JUBLPHARMA) Is Using Debt Extensively
Dec 02These 4 Measures Indicate That Jubilant Pharmova (NSE:JUBLPHARMA) Is Using Debt Extensively
Jul 26Is Jubilant Pharmova (NSE:JUBLPHARMA) A Risky Investment?
Dec 10Does Jubilant Pharmova (NSE:JUBLPHARMA) Have A Healthy Balance Sheet?
Jun 15Is Jubilant Pharmova (NSE:JUBLPHARMA) A Risky Investment?
Feb 15Recent updates
Jubilant Pharmova (NSE:JUBLPHARMA) Has A Somewhat Strained Balance Sheet
Mar 14Jubilant Pharmova Limited (NSE:JUBLPHARMA) Shares Fly 27% But Investors Aren't Buying For Growth
Dec 23These 4 Measures Indicate That Jubilant Pharmova (NSE:JUBLPHARMA) Is Using Debt Extensively
Dec 02These 4 Measures Indicate That Jubilant Pharmova (NSE:JUBLPHARMA) Is Using Debt Extensively
Jul 26Estimating The Fair Value Of Jubilant Pharmova Limited (NSE:JUBLPHARMA)
May 11Is Jubilant Pharmova (NSE:JUBLPHARMA) A Risky Investment?
Dec 10Jubilant Pharmova (NSE:JUBLPHARMA) Has Announced A Dividend Of ₹5.00
Aug 01Does Jubilant Pharmova (NSE:JUBLPHARMA) Have A Healthy Balance Sheet?
Jun 15Calculating The Intrinsic Value Of Jubilant Pharmova Limited (NSE:JUBLPHARMA)
Mar 22Is Jubilant Pharmova (NSE:JUBLPHARMA) A Risky Investment?
Feb 15Calculating The Intrinsic Value Of Jubilant Pharmova Limited (NSE:JUBLPHARMA)
Dec 20Here's Why It's Unlikely That Jubilant Pharmova Limited's (NSE:JUBLPHARMA) CEO Will See A Pay Rise This Year
Sep 15Here's Why Jubilant Pharmova (NSE:JUBLPHARMA) Can Manage Its Debt Responsibly
Aug 21Time To Worry? Analysts Are Downgrading Their Jubilant Pharmova Limited (NSE:JUBLPHARMA) Outlook
Jun 08An Intrinsic Calculation For Jubilant Pharmova Limited (NSE:JUBLPHARMA) Suggests It's 39% Undervalued
May 25Analysts Just Made A Major Revision To Their Jubilant Pharmova Limited (NSE:JUBILANT) Revenue Forecasts
Feb 10Estimating The Fair Value Of Jubilant Pharmova Limited (NSE:JUBILANT)
Feb 08
Shareholders Are Thrilled That The Jubilant Life Sciences (NSE:JUBILANT) Share Price Increased 217%
Jan 11Does Jubilant Life Sciences' (NSE:JUBILANT) CEO Salary Compare Well With Industry Peers?
Dec 31Read This Before Selling Jubilant Life Sciences Limited (NSE:JUBILANT) Shares
Dec 20Has Jubilant Life Sciences Limited's (NSE:JUBILANT) Impressive Stock Performance Got Anything to Do With Its Fundamentals?
Dec 08We Think Jubilant Life Sciences (NSE:JUBILANT) Can Stay On Top Of Its Debt
Nov 27What Kind Of Investors Own Most Of Jubilant Life Sciences Limited (NSE:JUBILANT)?
Nov 17Jubilant Life Sciences Limited Just Missed EPS By 15%: Here's What Analysts Think Will Happen Next
Nov 06If You Like EPS Growth Then Check Out Jubilant Life Sciences (NSE:JUBILANT) Before It's Too Late
Oct 27Estimating The Fair Value Of Jubilant Life Sciences Limited (NSE:JUBILANT)
Oct 15Does Jubilant Life Sciences' (NSE:JUBILANT) Share Price Gain of 96% Match Its Business Performance?
Oct 03Trade Alert: The Independent Non-Executive Director Of Jubilant Life Sciences Limited (NSE:JUBILANT), Arun Seth, Has Just Spent ₹1.1m Buying 233% More Shares
Sep 21How Much is Jubilant Life Sciences' (NSE:JUBILANT) CEO Getting Paid?
Sep 20Jubilant Life Sciences Limited Just Missed Earnings And Its Revenue Numbers Were Weaker Than Expected
Sep 08재무 상태 분석
단기부채: JUBLPHARMA 의 단기 자산 ( ₹38.8B )이 단기 부채( ₹18.9B ).
장기 부채: JUBLPHARMA 의 단기 자산( ₹38.8B )은 장기 부채( ₹42.4B ).
부채 대 자본 내역 및 분석
부채 수준: JUBLPHARMA 의 순부채 대 자기자본 비율( 45.3% )은 높음으로 간주됩니다.
부채 감소: JUBLPHARMA 의 부채 대 자기자본 비율은 지난 5년간 100.2% 에서 63% 로 감소했습니다.
부채 범위: JUBLPHARMA 의 부채는 영업 현금 흐름 ( 28.4% )에 의해 잘 충당되었습니다.
이자 보장: JUBLPHARMA 의 부채에 대한 이자 지급은 EBIT( 1.9 x 적용 범위)만큼 잘 덮이지 않음입니다.